FDA Grants Salix’s UCERIS Rectal Foam for Ulcerative Colitis Final Approval

FDA Grants Salix’s UCERIS Rectal Foam for Ulcerative Colitis Final Approval
The U.S. Food and Drug Administration (FDA) recently approved UCERIS (budesonide) rectal foam, developed by Salix Pharmaceuticals, to induce remission in patients suffering from active mild-to-moderate distal ulcerative colitis (UC) extended up to 40 cm from the anal verge. The therapy works through the use of corticosteroid foam, which is rectally administered, and it is indicated for use alone or

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *